Barclays raised the firm’s price target on Phibro Animal Health (PAHC) to $22 from $20 and keeps an Underweight rating on the shares following the fiscal Q2 beat. The company’s increased 2025 outlook includes the new MFA portfolio, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health Sees Strong Q2 Growth
- Phibro Animal Health Highlights Strong Earnings and Growth
- Phibro Animal Health: Sell Rating Due to Below-Expectation Financials and Competitive Concerns
- Phibro Animal Health sees FY25 revenue $1.25B-$1.30B, two estimates $1.32B
- Phibro Animal Health reports Q2 EPS 54c, consensus 45c